We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center.
- Authors
Reinglas, Jason; Gonczi, Lorant; Verdon, Christine; Bessissow, Talat; Afif, Waqqas; Wild, Gary; Seidman, Ernest; Bitton, Alain; Lakatos, Peter L.
- Abstract
<bold>Background: </bold>Evaluating clinical data on the safety and efficacy of vedolizumab (VDZ) in 'real-world' setting is still desirable. Recent reports have raised concerns that arthralgia may be associated with VDZ.<bold>Aims: </bold>The aim of this study is to present clinical experience with VDZ from a tertiary IBD center.<bold>Methods: </bold>Retrospective chart reviews were performed of consecutive patients exposed to VDZ between 2015 and 2018. Clinical, biomarker, and endoscopic efficacy and safety data were evaluated.<bold>Results: </bold>A total of 130 IBD (75CD, 55UC) patients were included. Median duration of VDZ therapy was 65 weeks. Probability of drug discontinuation was 4.9% and 9.4% at 1 and 2 years. Dose intensification was more frequent in CD compared to UC (at 1 and 2 years: 64.8/87.9% vs. 26.5/35.7%, p < 0.001). Clinical remission rates at 3-, 6- and 12 months were 44.4%, 71.4% and 77.1% in UC, and 9.1%, 26.7% and 29.2% in CD patients, respectively. Prior use of multiple biologic agents was associated with diminished efficacy of VDZ in CD. Three new cases of arthralgia were encountered during follow-up.<bold>Conclusion: </bold>Vedolizumab (VDZ) therapy displayed good drug sustainability and clinical efficacy in a population with severe disease phenotype and high rates of previous anti-TNF failure. Frequent dose intensification was required. The safety profile was good, and no association between newly onset arthralgia and VDZ therapy was observed.
- Subjects
THERAPEUTIC use of monoclonal antibodies; ULCERATIVE colitis; CROHN'S disease; INFLAMMATORY bowel diseases; SPECIALTY hospitals; JOINT pain; RETROSPECTIVE studies; SEVERITY of illness index; TREATMENT effectiveness; DRUGS; DOSE-effect relationship in pharmacology; PATIENT compliance; GASTROINTESTINAL agents
- Publication
Digestive Diseases & Sciences, 2020, Vol 65, Issue 7, p2046
- ISSN
0163-2116
- Publication type
journal article
- DOI
10.1007/s10620-019-05982-z